Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

p53 À¯ÀüÀÚÀÇ ÀÎü ´ëÀå¾Ï ¼¼Æ÷ÁÖ ÀÌÀÔ¿¡ ´ëÇÑ ¼¼Æ÷ »ý¹°ÇÐÀû È¿°ú Effects of Wild-type p53 Gene Transfection into Human Colon Cancer Cell Line

´ëÇѾÏÇÐȸÁö 1999³â 31±Ç 2È£ p.367 ~ 376
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇö¿Á/Hyun Ok Kim ±è¿ìÈ£/¹è¼öÀÎ/ÀÌÇý¿ø/±èÁ¾Àç/È«¼º·Ä/±è¿ëÀÏ/Woo Ho Kim/Soo In Bae/He Won Lee/Chong Jai Kim/Sung Youl Hong/Yong Il Kim

Abstract

¼­·Ð
´ëÀå¿¡ »ý±â´Â ¾ÏÁ¾Àº Çѱ¹ÀÎÀÇ ´ëÀå¿¡ ¹ß»ýÇÏ´Â ¾Ç¼º Á¾¾çÀÇ 95%¸¦ Â÷ÁöÇÏ´Â ÁÖ¿ä Áúȯ
À̸ç, ±× ¹ß»ý·üÀÌ Çظ¶´Ù Áõ°¡ Ãß¼¼¸¦ º¸ÀÌ°í ÀÖ´Ù. ±×°£ ´ëÀå ¾ÏÁ¾ÀÇ Á¾¾ç ¹ß»ý ¹× ÁøÇà
°úÁ¤¿¡ °üÇؼ­´Â ºñ±³Àû ´Ù¾çÇÑ ¿¬±¸°¡ ÀÌ·ç¾îÁ® ¿ÔÀ¸¸ç, ƯÈ÷ ÃÖ±Ù ºÐÀÚ»ý¹°ÇÐ ¿¬±¸°¡ È°
¹ßÇØÁö¸é¼­ ´ëÀå ¾ÏÁ¾¿¡¼­ ³ªÅ¸³ª´Â À¯ÀüÀû º¯È­µé¿¡ ´ëÇÑ ¸¹Àº º¸°í°¡ ¹ßÇ¥µÇ¾ú´Ù.
ÇöÀç±îÁö º¸°íµÈ ´ëÀå¾ÏÁ¾¿¡¼­ÀÇ À¯ÀüÀÚ º¯È­¸¦ º¸¸é, Ãʱ⿡ APC À¯ÀüÀÚÀÇ ¼Ò½Ç·ÎºÎÅÍ
½ÃÀÛÇÏ°í, À̾ DNA hypomethylation, K-ras À¯ÀüÀÚ º¯ÀÌ, DCC À¯ÀüÀÚ º¯ÀÌ, ±×¸®°í
p53 Á¾¾ç¾ïÁ¦ À¯ÀüÀÚÀÇ º¯ÀÌ¿¡ ÀÇÇؼ­ ¾ÏÁ¾ÀÌ ¹ß»ýÇÑ´Ù. Á¾¾ç¾ïÁ¦ À¯ÀüÀÚ Áß¿¡¼­ p53 À¯Àü
ÀÚ¿¡¼­´Â ´ë¸³À¯ÀüÀÚ Áß Çϳª°¡ »ó½Ç(LOH)µÇ¾î, ³ª¸ÓÁö ÇϳªÀÇ ´ë¸³ À¯ÀüÀÚ¿¡¼­´Â Á¡µ¹¿¬
º¯ÀÌ°¡ ¹ß»ýÇÑ´Ù°í º¸°íµÇ¾î ÀÖ´Ù. Á¾¾ç¾ïÁ¦ À¯ÀüÀÚ p53Àº ÀÎü ¿°»öü 17¹ø ´Ü¿Ï(17p13.1)
¿¡ ÀÖ´Â ÇÙÀÎ»ê ´Ü¹éÁú·Î ºÐÀÚ·®Àº 53k ´ÞÅæÀÌ´Ù. ÁÖ·Î axon 5, 6, 7, 8ºÎÀ§°¡ DNA binding
site ÇØ´çÇϸç, ÀÌµé ºÎÀ§¿¡¼­ º¯ÀÌ°¡ ºó¹øÇÏ°Ô ¹ß»ýÇÏ°í ÀÖ´Ù.
ÀÚ¿¬ÇüÀÇ p53 À¯ÀüÀÚÀÇ ±â´ÉÀº ¾Ï¼¼Æ÷ó·³ º¯¼ºµÈ ¼¼Æ÷¸¦ ¼¼Æ÷ ¼ºÀåÁÖ±âÀÇ G1 ±â¿¡¼­ Á¤
Áö½ÃÄÑ ¼¼Æ÷ ¼ºÀåÀ» ¾ïÁ¦ÇÏ°Ô ÇÑ´Ù. À̶§¿¡ ¼Õ»óµÈ DNA¸¦ ¼ö¼±ÇÏ¿© Á¤»óÀ¸·Î ¸¸µé°Å³ª, ¼Õ
»óÀÌ º¹±¸µÇÁö ¸øÇÒ °æ¿ì¿¡´Â apoptosis¸¦ ÅëÇØ °á°úÀûÀ¸·Î ¾Ï ¹ß»ýÀ» ¾ïÁ¦ÇÏ°Ô µÈ´Ù. ±×·¯
³ª µ¹¿¬º¯ÀÌÇü p53 À¯ÀüÀÚÀÇ °æ¿ì¿¡´Â ÀÚ¿¬Çü P53 À¯ÀüÀÚÀÇ ±â´ÉÀ» ¾ïÁ¦Çϸç, ³ª¾Æ°¡¼­ º¯
¼ºµÈ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù. µ¹¿¬º¯ÀÌÀÇ ÇüÅ´ p53 À¯ÀüÀÚÀÇ ºÎºÐÀû ¶Ç´Â ÀüüÀû ¼Ò½Ç
(LOH), Á¡µ¹¿¬º¯ÀÌ(point mutation), ƲÀ̵¿ µ¹¿¬º¯ÀÌ(frame shift mutation) ¹× »ðÀÔ
(insertion) µî ´Ù¾çÇÑ ¾ç½ÄÀ» ÃëÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ Áß Á¦ÀÏ ºó¹øÇÑ °ÍÀº Á¡µ¹¿¬º¯ÀÌÀÌ´Ù. Á¡
µ¹¿¬º¯ÀÌ´Â °á°úÀûÀ¸·Î p53 ´Ü¹é ±¸Á¶¿¡ º¯ÇüÀ» ÃÊ·¡ÇÏ¿© Á¾¾ç¾ïÁ¦ À¯ÀüÀÚÀÇ ±â´ÉÀ» »ó½Ç
ÇÏ°Ô µÈ´Ù.
º» ¿¬±¸¿¡¼­´Â ÀÎü ´ëÀå¾Ï ¼¼Æ÷ÁÖ¿¡¼­ p53À¯ÀüÀÚÀÇ »óŸ¦ ºÐ¼®ÇÏ°í, º¯ÀÌ ¼¼Æ÷ÁÖ¿¡ ÀÚ
¿¬Çü p53 À¯ÀüÀÚ¸¦ ÀÌÀÔÇÔÀ¸·Î½á ¼¼Æ÷ÀÇ Á¤»óÀûÀÎ ±â´ÉÀ» ȸº¹ÇÒ ¼ö Àִ°¡¸¦ °ËÁõÇÔÀ¸·Î
½á À¯ÀüÀÚÄ¡·á¿¡ ´ëÇÑ ±âÃʸ¦ ¸¶·ÃÇÏ°íÀÚ ÇÏ¿´´Ù.

Purpose : In colon cancer, the most frequent genetic alteration is found in p53 tumor
suppressor gene residing on the short arm of chromosome 17. In order to investigate the
significance of wild-type p53, we transfected wild type p53 into human colon cancer cell
lines and analysed their biologic effects.
Materials and Methods : For analysis of p53 status in cell lines, polymerase chain
reaction-single stranded conformation polymorphism (PCR-SSCP), PCR-direct sequencing
and Western blot analysis were employed. Transient transfection with liposome-p53
complex was followed by cell biologic assay.
Results : We found that twelve of fifteen human colon cancer cell lines showed
mutation of p53 by PCR-SSCP method. These results almost corresponded to p53
protein accumulations assessed by Western blot using PAb1801. After transfection with
lipofect-AMINE and wild type p53 complex on p53 mutant type cell line (LS1034),
viability was reduced to 17.9%, and invasiveness was reduced to 37.3%. Morphologically,
wild type p53 transfected cells showed lumen formation and apoptosis after induction of
differ-entiation by Matrigel.
Conclusion : Wild type p53 transfection into p53 mutated colon cancer cell line
resulted in restoration of tumor suppressor effect of p53, and this model would be one
of the experimental systems for p53-based gene therapy.

Å°¿öµå

Colon cancer cell lines; p53 tumor suppressor gene; Liposome; Transfection;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS